Bisphosphonate drug market seen reaching $7.04 billion by 2030
The Business Research Company says the global bisphosphonate drug market is expanding on rising osteoporosis cases, an aging population and broader use of injectable therapies. The market is projected to grow from $5.28 billion in 2025 to $7.04 billion by 2030, with North America leading and Asia-Pacific set to grow fastest.
Why it matters: - The bisphosphonate drug market is tied to osteoporosis treatment and fracture prevention, which are becoming more important as populations age. - Growth in this market signals rising demand for therapies that help preserve bone density and reduce fracture risk. - The forecast also points to broader use of preventive bone health care and oncology support treatments.
What happened: - The Business Research Company released its Bisphosphonate Drug Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report projects the market will rise from $5.28 billion in 2025 to $5.61 billion in 2026. - The report forecasts the market will reach $7.04 billion by 2030. - The report gives the market a 6.2% CAGR for the historical period and a 5.8% CAGR through 2030. - Download the free sample report. - Read the full report.
The details: - Bisphosphonates are medications used to prevent bone density loss. - The drugs are prescribed to manage or prevent osteoporosis by slowing bone breakdown. - Their main purpose is to strengthen bones and lower fracture risk. - Rising osteoporosis prevalence is a major driver of demand. - Healthy Bones Australia reported in August 2024 that there were about 193,482 fractures linked to osteoporosis and osteopenia in 2023. - Healthy Bones Australia said that figure is expected to rise 34% to 237,632 fractures by 2033. - The report cites an aging global population, natural bone density loss with age, lifestyle factors and inadequate preventive care as additional drivers. - The report says increasing use of oral bisphosphonate therapies helped support historical growth. - The report says wider adoption of injectable bisphosphonate therapies will support future growth. - The report says generic versions and preventive bone health strategies will also help expand demand. - The report highlights growth in postmenopausal osteoporosis treatment, long-acting injectable formulations, generic drug options and cancer-related bone loss treatments.
Between the lines: - The market outlook reflects a shift from treating bone loss after diagnosis toward broader prevention and longer-duration therapy options. - Injectable and long-acting formulations could matter most where adherence to oral treatment is a challenge. - Growth in generic availability suggests price sensitivity will remain important, even as demand rises. - Oncology use indicates bisphosphonates are not just a bone-health category but also part of supportive cancer care.
What's next: - North America held the largest market share in 2025, supported by established healthcare infrastructure, advanced treatment protocols and higher awareness of bone health. - Asia-Pacific is expected to be the fastest-growing region through the forecast period. - The report cites improving healthcare access, rising osteoporosis incidence and expanding pharmaceutical manufacturing in Asia-Pacific as growth factors. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspots infographics, and updated graphics and tables. - Contact details listed in the release include Saumya Sahay at marketing@tbrc.info and The Business Research Company’s social media links.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Australia Globe
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.